Shares of Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) hit a new 52-week high on Friday . The stock traded as high as C$25.00 and last traded at C$22.68, with a volume of 2166709 shares changing hands. The stock had previously closed at C$21.52.
Several analysts have recently weighed in on the company. Royal Bank Of Canada lowered their target price on Valeant Pharmaceuticals International to C$22.50 and set a “sector perform” rating for the company in a research note on Friday, October 20th. TD Securities upgraded Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 target price for the company in a research note on Wednesday, November 8th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of C$22.50.
In related news, Director Schutter Richard Urbain De purchased 10,000 shares of Valeant Pharmaceuticals International stock in a transaction dated Friday, November 17th. The shares were acquired at an average price of C$14.33 per share, with a total value of C$143,300.00.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.